Equity Brief · Healthcare2026-05-20
BMY·Healthcare

Bristol-Myers Squibb Company

Sentinellis health

7.4/10

Financially healthy

Market capitalisation

$119.1B

Revenue (TTM)

$48.2B

§ I · AI Analysis

The brief

Bristol-Myers Squibb discovers, develops, manufactures, and sells prescription medicines worldwide, focusing on cancer treatments (Opdivo, Yervoy, Breyanzi), immune system drugs (Orencia, Zeposia), blood disorder treatments (Reblozyl, Revlimid), and cardiovascular medicines (Eliquis) [Yahoo Finance]. The company sells through wholesalers, specialty pharmacies, hospitals, and government agencies across global markets [Yahoo Finance].

Bristol-Myers Squibb is a large pharmaceutical company that develops and sells drugs for cancer, immune diseases, heart conditions, and neurological disorders [Yahoo Finance]. The company generates $48.2B in annual revenue, maintains a $119B market cap, and is financially healthy with strong cash flow [Yahoo Finance]. Recent news highlights aggressive AI partnerships with Anthropic and Tempus AI to accelerate drug discovery, plus a major $1B manufacturing expansion in Houston [Yahoo Finance].

Bristol-Myers Squibb is financially healthy with strong profitability and solid cash generation, though revenue is flat year-over-year [Yahoo Finance].

Synthesis Claude Sonnet 4.5Confidence 8/10

§ II · Recent news

What moved

6 stories · ranked by relevance

  • macro2026-05-20

    Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations

    Yahoo Finance

  • macro2026-05-19

    How The Bristol Myers Squibb (BMY) Story Is Shifting Around Pipeline Hopes And Patent Risks

    Simply Wall St

  • macro2026-05-20

    Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery

    Yahoo Finance

  • macro2026-05-18

    Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts

    Benzinga

  • macro2026-05-19

    Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

    Zacks

  • macro2026-05-18

    Tempus AI And BMS Deepen AI Drug Development Ties As Losses Persist

    Simply Wall St

Premium · Free with any account

Risk Analysis

Opportunities

Full Financials

Executive Team

Unlock the full Bristol-Myers Squibb Company analysis

Create a free account to access the complete AI-generated report with inline citations.

  • Risks, opportunities, and red flags with sources
  • 100+ financial metrics with charts and benchmarks
  • Full news summaries with source links
  • Executive team and compensation details
  • PDF export for offline use
Read my free brief3 free reports · No credit card

§ III · Related

You might also read

Same sector · Healthcare or comparable health

Want this for your watchlist?

Read three companies free. No card.

Get 3 free reports